March 16, 2021
Forward-Looking Statements

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this presentation may include, without limitation, statements regarding (i) plans and objectives of management for operations of Haemonetics Corporation (the “Company”), including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products, plans or objectives related to the Operational Excellence Program, and plans or objectives related to the Company’s acquisition of Cardiva Medical, Inc. (“Cardiva”), including statements regarding the anticipated benefits to the Company arising from the acquisition; (ii) the completion, timing and size of the over-allotment option to the Company’s convertible note offering, including expectations regarding actions of the option counterparties and their respective affiliates; (iii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the share repurchase program and the Company’s acquisition of Cardiva, (iv) the impact of the COVID-19 pandemic on the Company’s operations, availability and demand for its products, and future financial performance, and (v) the assumptions underlying or relating to any statement described in points (i) through (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the risk that some or all of the over-allotment option to the Company’s convertible note offering will not be exercised; changes as a result of market conditions, including market interest rates, fluctuations in the trading price and volatility of the Company’s common stock; the impact of the COVID-19 pandemic, including the scope and duration of the outbreak; government actions and restrictive measures implemented in response; availability and demand for the Company’s products; the Company’s ability to implement as planned and realize estimated cost savings from the Operational Excellence Program; the Company’s ability to execute business continuity plans; risks arising from the Company’s acquisition of Cardiva, including the increased leverage and debt servicing costs from the Company’s use of debt to finance the transaction, and any failure to realize the anticipated benefits of the transaction; the impact of share repurchases on the Company’s stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness; technological advances in the medical field and standards for transfusion medicine and the Company’s ability to successfully offer products that incorporate such advances and standards; product quality; market acceptance; regulatory uncertainties, including in the receipt or timing of regulatory approvals; the effect of economic and political conditions; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.
Management’s use of Non-GAAP Financial Measures

This presentation contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. When used in this presentation, organic revenue growth excludes the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures. Adjusted operating income and adjusted earnings per diluted share exclude restructuring and turnaround costs, deal amortization expenses, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation, transaction costs, gains and losses on dispositions and certain legal charges. Adjusted earnings per diluted share also excludes the tax impact of these items. Free cash flow before restructuring and turnaround is defined as cash provided by operating activities less capital expenditures, net of the proceeds from the sale of property, plant and equipment and does not include net cash proceeds received upon the sale of the Company’s Braintree corporate headquarters. A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included on the Company’s website at www.haemonetics.com.
Global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare.
Long-term value creation strategy that is supported by multiple value drivers

Corporate Strategy

- Compete in winning segments and geographies
- Achieve leading position in each segment where we compete
- Deliver superior short-term and long-term operating performance (ROIC)

Value drivers

1. Plasma market
2. Hospital market
3. Mergers & Acquisitions
4. Innovation Agenda
5. Operational Excellence
6. Capital Allocation
FY20 revenue snapshot in the customer-centric business unit structure

<table>
<thead>
<tr>
<th>Plasma</th>
<th></th>
<th>Hospital</th>
<th></th>
<th>Service</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>% Revenue ex. NA³</td>
<td>7%</td>
<td>% Revenue ex. NA³</td>
<td>43%</td>
<td>% Revenue ex. NA³</td>
<td>55%</td>
</tr>
<tr>
<td>% Disp. revenue²</td>
<td>92%</td>
<td>% Disp. revenue²</td>
<td>70%</td>
<td>% HM⁴ revenue</td>
<td>48%</td>
</tr>
<tr>
<td>% NA disp. revenue (excluding solutions)³</td>
<td>78%</td>
<td>% NA disp. revenue (excluding solutions)³</td>
<td>378%</td>
<td>% NA disp. revenue (excluding solutions)³</td>
<td>78%</td>
</tr>
</tbody>
</table>

**FY20 Revenue**

- **Plasma:**
  - % Revenue ex. NA³: 7%
  - % Disp. revenue²: 92%
  - % NA disp. revenue (excluding solutions)³: 78%

- **Hospital:**
  - % Revenue ex. NA³: 43%
  - % Disp. revenue²: 70%
  - % HM⁴ revenue: 48%

- **Blood Center:**
  - % Revenue ex. NA³: 68%
  - % Disp. revenue²: 93%

- **Service:**
  - % Revenue ex. NA³: 55%

1. Revenue excluding North America
2. Disposables revenue
3. North America (NA) disposables revenue excluding liquid solutions
4. Hemostasis Management/TEG

Fiscal 2020 revenue percentages do not reflect the impact of certain strategic exits of product lines, acquisitions and divestitures that occurred in fiscal 2021. For more information please refer to Haemonetics’ Form 10-Q for the third quarter ended December 26, 2020 as filed with the SEC, as well as the Company’s earnings release and analytical tables and supplemental information for the third quarter available at [https://haemonetics.gcs-web.com/investor-overview](https://haemonetics.gcs-web.com/investor-overview).
Leading position in Plasma with modern, integrated technology solutions

Business Model
- Plasmapheresis
  - Capital/Disposables
  - NexSys PCS®/PCS®2
  - Growth

Product Portfolio
- Software
  - Software Solutions
  - NexLynk DMS®
  - Developing

Market Lifecycle
- Market Position
  - 1

Competition
- Competition
  - Fresenius Fenwal (Aurora), Other (OUS)
  - MAK, homegrown

NexLynk DMS®
- Donor management software

Value-added software “apps”
Plasma market continues to show strong growth and HAE is prepared to support this opportunity

<table>
<thead>
<tr>
<th>Robust growth in plasma-derived therapeutics</th>
<th>Therapeutic alternatives viewed as early stage</th>
<th>Increased production capacity</th>
</tr>
</thead>
<tbody>
<tr>
<td>~8% Historical fractionation capacity(^3)</td>
<td>Pre-clin. Recombinant IgG Pre-clin. FcRn</td>
<td>~2X (45M → 90M liters)</td>
</tr>
<tr>
<td>Est ’15–’23 CAGR(^1)</td>
<td>PII</td>
<td>~9% ’13–’17 CAGR(^4)</td>
</tr>
<tr>
<td>~756 Registered clinical trials(^2)</td>
<td></td>
<td>~12% ’13–’17 CAGR(^4)</td>
</tr>
<tr>
<td>Indications</td>
<td>US plasma center collections</td>
<td></td>
</tr>
<tr>
<td>Formulations</td>
<td></td>
<td># of US plasma centers</td>
</tr>
<tr>
<td>Diagnosis rates</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Increased Production Capacity

- **Historical Fractionation Capacity**
  - \(45M \rightarrow 90M\) liters
  - \(\approx 2X\)
  - \(^{3}\) ’13–’17 CAGR\(^4\)

### Plasma Market Growth

- **Therapeutic Alternatives**
  - Pre-clin.
  - Recombinant IgG
  - FcRn

- **PII**

### Statistics

- **Registered Clinical Trials**
  - \(\approx 756\)
  - \(^{2}\)

- **Indications**

- **Formulations**

- **Diagnosis Rates**
  - \(\approx 50\%\)

- **Increase in Plasma Collection Disposables Capacity**
  - \(\approx 50\%\)

- **Number of US Plasma Centers**
  - \(\approx 12\%\)
  - ’13–’17 CAGR\(^4\)

---

2. clinicaltrials.gov 8/10/18 ClinicalTrials “plasma derived” search return

---

© 2021 Haemonetics Corporation
NexSys platform improves customer identified tangible value drivers

**Plasma Yield**
- Increased Plasma yield by 18-26ml per donation on average through YES® Technology\(^1,2\)

**Productivity**
- ~20% improvement in door to door efficiency\(^3\)
- Increased labor effectiveness
- Business Optimization support
- 10% reduction in cost to collect a liter of plasma\(^4\)

**Quality and Compliance**
- >91% reduction in key quality events (overdraws, documentation errors)\(^3\)
- Bi-directional, paperless workflow helps eliminate errors and enforces compliance

**Donor Experience**
- Reduced donation times
- Increased donor engagement and satisfaction
- Improved staff responsiveness

---

1. Plasma yield enhancing solution; YES® Technology is available in the United States only
3. In-market results from NexSys PCS/NexLynk DMS implementations baselined versus Haemonetics PCS®2 device use, non bi-directionally integrated with Haemonetics DMS
4. Company’s internal estimates
The Persona™ plasma collection solution enables the new Persona nomogram

**Persona™** a proprietary integrated plasma collection solution built upon the NexSys PCS® platform, is the first and only donor-tailored solution clinically shown to yield +9% to 12%\(^1\) more plasma per donation on average to maximize both cost-efficient output and patient impact.

Leading positions within four synergistic Hospital markets with state-of-the-art product offering

<table>
<thead>
<tr>
<th>Business Model</th>
<th>Product Portfolio</th>
<th>Market Lifecycle</th>
<th>Competition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemostasis Management</td>
<td>Capital/Disposables</td>
<td>Developing</td>
<td>IL (ROTEM), Stago (HemaSonics)</td>
</tr>
<tr>
<td>Cell Salvage</td>
<td>Capital/Disposables</td>
<td>Mature</td>
<td>LivaNova, Fresenius, Medtronic</td>
</tr>
<tr>
<td>Transfusion Management</td>
<td>Software Solutions</td>
<td>Mature/Developing</td>
<td>Cerner, Mediware / MSoft</td>
</tr>
<tr>
<td>Vascular Closure Devices</td>
<td>Disposables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Acquisition</td>
<td>Vascade®/Vascade MVP®</td>
<td>Mature/Developing</td>
<td>Terumo, Abbott Cardinal Health / Manual Compression</td>
</tr>
</tbody>
</table>

- TEG® 5000, TEG®6s & TEG Manager, ClotPro
- Cell Saver® Elite®
- SafeTrace Tx®/BloodTrack®
- TEG®6s
- BloodTrack®
- Cell Saver® Elite®
- Vascade MVP®
- Cell Saver® Elite®
- Vascade MVP®
- TEG®6s

© 2021 Haemonetics Corporation
Cardiva Medical is growth accretive and aligned with the corporate strategy

**Winning Markets**

**ELECTROPHYSIOLOGY PROCEDURES**
~$330M U.S. market¹ growing rapidly

**CORONARY & PERIPHERAL PROCEDURES**
~$1.1B U.S. market¹

**Leading Position**

**VASCADE® MVP**

Only FDA approved Vascular Closure Device for use following cardiac ablation procedures requiring two or more access sites within the same vessel.

**VASCADE®**

Only Vascular Closure Device proven to reduce access site complications

**Superior Results**

- Immediately accretive to revenue growth and adjusted gross margins
- Leverage HAE’s G&A infrastructure to accelerate profitability
- Expand VASCADE reach through HAE’s global commercial capabilities
- Opportunity for call point expansion for Hemostasis Management

---

¹ 2019 projected Total Addressable Market based on 2019 Decision Resource Group reported procedures, Company reported percutaneous access sites per procedure, and Company ASPs.
² Compared to manual compression
Strong market opportunity reinforces Hospital as a growth driver for Haemonetics

**HAE’s Hospital Near-term Market Opportunity in our Core Markets**

- **Cell Salvage\(^1\)**
  - Share of voice:
    - CV Surgery
    - Trauma
  - $200M

- **Transfusion Management**
  - Next generation BBIS\(^3\)
  - Smarter and safer BIMS\(^5\)
  - $300M

- **Vascular Closure Devices**
  - Vascular Closure
    - Interventional Cardiology
    - Electrophysiology
  - $1.4B

- **Hemostasis Management\(^1\)**
  - Standard of care and market growth
  - Attractive core markets:
    - Interventional Cardiology
    - CV Surgery
    - Trauma
  - Hospital growth platform
  - $2.4B

1. Annual disposables market only in core markets
2. HIMSS Logic Database, Internal Analysis & Calculations
3. Blood Bank Information System
4. Includes US TAM only
5. Blood Inventory Management System

---

© 2021 Haemonetics Corporation
Three Blood Center portfolios that offer safe, reliable blood collection solutions

<table>
<thead>
<tr>
<th>Business Model</th>
<th>Product Portfolio</th>
<th>Market Lifecycle</th>
<th>Competition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apheresis</td>
<td>Whole Blood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital/Disposables</td>
<td>Disposables</td>
<td>Mature</td>
<td>Fresenius, Terumo</td>
</tr>
<tr>
<td>MCS+ Suite, ACP-215</td>
<td>Manual Blood Collections and Filtration</td>
<td>Mature</td>
<td>Fresenius, Terumo, Macopharma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Blood Center market remains challenging
Significant cash flow opportunity

**Market:**
- Decline in blood transfusion rates due to:
  - Decline in invasive surgeries
  - Improvements in BMP
  - Pharmaceuticals
- High-yield, multi-dose collections are becoming a new standard
- Tender-driven business creates pricing pressures (mostly OUS)

**HAE Opportunity:**
- Complexity reduction through:
  - Standardized technology
  - Optimized product portfolio
  - Reduced commercial footprint
- Customized pricing strategies
- Strategic resource allocation
- Improvements in cost of goods sold
- Focus on profitability and cash flow
Innovation Agenda to support long-term growth

**Plasma**
- Greater plasma collection
- Better donor engagement
- Improved safety

**Hospital**
- Broader indications for TEG®
- Region specific innovation
- Integrated software solutions

**Blood Center**
- Safer donations & end products
- Customized donor collections
- Increased product yield

---

**VOC & Customer Engagements**

**Clinical & Real-world Evidence**

**Software & Digital Solutions**
Our productivity programs reduce inefficiency and free up resources to fund growth investments

<table>
<thead>
<tr>
<th>Complexity Reduction Program³</th>
<th>Operational Excellence Program</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Timing</strong></td>
<td>FY18 – FY20</td>
</tr>
<tr>
<td><strong>Scope</strong></td>
<td>G&amp;A, productivity</td>
</tr>
<tr>
<td>Gross Savings (target)</td>
<td>$80M+</td>
</tr>
<tr>
<td>Net Savings ¹ (target)</td>
<td>Modest</td>
</tr>
<tr>
<td>CAPEX</td>
<td>N/A</td>
</tr>
<tr>
<td>One-time program costs²</td>
<td>$50 - $60M</td>
</tr>
</tbody>
</table>

1. The amount of savings estimated to drop through to the bottom line by the end of the program
2. Include restructuring charges over the course of the program. These charges will be excluded from the adjusted results.
3. The Complexity Reduction Program has been substantially completed at the end of FY’20 having delivered gross savings of $80M+ and resulted in total cumulative one-time costs of $58.7M as of December 26, 2020.
Capital allocation priorities to support organic and inorganic value creation

1. Organic business needs (R&D, S&M, CAPEX)

2. Inorganic growth opportunities (including M&A)

3. Share repurchases
Superior results: Sustaining revenue growth

Revenue (US $ Millions)

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (US $ Millions)</th>
<th>FY'16</th>
<th>FY'17</th>
<th>FY'18</th>
<th>FY'19</th>
<th>FY'20</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY'16</td>
<td>$910</td>
<td>0%</td>
<td>-3%</td>
<td>2%</td>
<td>7%</td>
<td>2%</td>
</tr>
<tr>
<td>FY'17</td>
<td>$886</td>
<td>1%</td>
<td>1%</td>
<td>2%</td>
<td>7%</td>
<td>6%</td>
</tr>
<tr>
<td>FY'18</td>
<td>$904</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY'19</td>
<td>$968</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY'20</td>
<td>$988</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Adjusted for the 53rd week in FY’16. Please refer to the earnings release for FY’16 for more detail.
2. Organic revenue growth excludes the impact of currency, product line end-of-life decisions as well as acquisition and divestiture activities.

© 2021 Haemonetics Corporation
Superior results: Stronger Operating and Financial leverage

<table>
<thead>
<tr>
<th>Operating Margin¹</th>
<th>Earnings Per Share</th>
<th>Cash Flow</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FY16</td>
<td>FY20</td>
</tr>
<tr>
<td>GAAP</td>
<td>(5%)</td>
<td>10%</td>
</tr>
<tr>
<td>Adjusted²</td>
<td>13%</td>
<td>22%</td>
</tr>
</tbody>
</table>

1. Operating Margin percentage is calculated as Operating Income/Loss divided by Revenue (as Reported); Adjusted Operating Margin percentage is calculated as Adjusted Operating Income divided by Adjusted Revenue.
2. For more information, including a reconciliation of GAAP to non-GAAP adjusted results, please refer to the Company’s earnings releases for the applicable periods at [http://haemonetics.gcs-web.com/](http://haemonetics.gcs-web.com/).
3. Free cash flow before restructuring & turnaround does not include net cash proceeds of $15.0 million from the sale of the Company’s Braintree corporate headquarters in the second quarter of fiscal 2020.
FY’21 YTD results were impacted by COVID-19

<table>
<thead>
<tr>
<th>GAAP</th>
<th>YTD Q3 FY’21</th>
<th>YTD Q3 FY’20</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$ 645</td>
<td>$ 750</td>
<td>-14%</td>
</tr>
<tr>
<td>Operating Income (OI)</td>
<td>$ 111</td>
<td>$ 77</td>
<td>43%</td>
</tr>
<tr>
<td>OI Margin%</td>
<td>17.2%</td>
<td>10.3%</td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>$ 1.77</td>
<td>$ 1.13</td>
<td>57%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adjusted¹</th>
<th>YTD Q3 FY’21</th>
<th>YTD Q3 FY’20</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$ 645</td>
<td>$ 752</td>
<td>-14%</td>
</tr>
<tr>
<td>Operating Income (OI)</td>
<td>$ 124</td>
<td>$ 171</td>
<td>-27%</td>
</tr>
<tr>
<td>OI Margin%</td>
<td>19.2%</td>
<td>22.7%</td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>$ 1.89</td>
<td>$ 2.61</td>
<td>-28%</td>
</tr>
</tbody>
</table>

¹. For more information, including a reconciliation of GAAP to non-GAAP adjusted results, please refer to the Company’s earnings releases for the applicable periods at [http://haemonetics.gcs-web.com/](http://haemonetics.gcs-web.com/)
Well-positioned to create long-term value

Our 5-year Turnaround plan

Accelerate growth
- NexSys PCS® / NexLynk DMS® roll-out
- Accelerated growth in Hospital
- Inorganic growth opportunities

Transform
- BU-centric, performance-driven culture
- Lean, improved operating model
- Complexity Reduction Initiative (CRI)

Stabilize
- Stabilize Blood Center
- Rationalize portfolio

Fast growing, innovative company that outpaces the market

FY17  FY19  FY21